ClinicalTrials.gg
CompletedNCT01375751RUTHERFORDUpdated Nov 15, 2022Results posted

Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study

A Phase 2 interventional study of Evolocumab and Placebo in Hypercholesterolemia, Familial, sponsored by Amgen. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-15.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145), compared with placebo, on percent change from baseline in LDL-C in adults with heterozygous familial hypercholesterolemia (HeFH).

02

Conditions studied

  • Hypercholesterolemia, Familial

Keywords

  • Heterozygous Familial Hypercholesterolemia
  • Proprotein convertase subtilisin/kexin type 9 (PCSK9)
03

In context

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

This study's enrollment of 168 is above the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.

Browse Hyperlipoproteinemia Type II studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 18 to ≤ 75 years of age
  • Diagnosis of heterozygous familial hypercholesterolemia by having met the diagnostic criteria outlined by the Simon Broome Register Group (Scientific Steering Committee 1991)
  • On an approved statin, with or without ezetimibe, with stable dose(s) for at least 4 weeks
  • Fasting Low-Density Lipoprotein Cholesterol (LDL-C) ≥ 100 mg/dL
  • Fasting triglycerides ≤ 400 mg/dL

Exclusion criteria

Exclusion Criteria:

  • Homozygous familial hypercholesterolemia
  • Low-Density Lipoprotein (LDL) or plasma apheresis within 12 months prior to randomization
  • (NYHA) III or IV heart failure, or known \< 30%
  • Uncontrolled cardiac arrhythmia
  • Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization
  • Type 1 diabetes; newly diagnosed or poorly controlled type 2 diabetes ( > 8.5%)
  • Uncontrolled hypertension
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
168 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo subcutaneous injection once every 4 weeks for 12 weeks.

    Biological: Placebo

  • Experimental
    Evolocumab 350 mg

    Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

    Biological: Evolocumab

  • Experimental
    Evolocumab 420 mg

    Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

    Biological: Evolocumab

Interventions

  • BiologicalEvolocumab

    Administered by subcutaneous injection

    Also known as: AMG 145, Repatha

  • BiologicalPlacebo

    d by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

    LDL-C was measured using ultracentrifugation.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Absolute Change From Baseline in LDL-C at Week 12

    LDL-C was measured using ultracentrifugation.

    Time frame: Baseline and Week 12

  2. Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (HDL-C) at Week 12

    Time frame: Baseline and Week 12

  3. Percent Change From Baseline in Apolipoprotein B at Week 12

    Time frame: Baseline and Week 12

  4. Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12

    Time frame: Baseline and Week 12

  5. Percent Change From Baseline in Apolipoprotein B /Apolipoprotein A-1 Ratio at Week 12

    Time frame: Baseline and Week 12

07

Results

Posted Sep 29, 2015

Participant flow

Men and women 18 to to 75 years of age, with a diagnosis of heterozygous familial hypercholesterolemia, fasting low-density lipoprotein cholesterol (LDL-C) of ≥ 100 mg/dL, and fasting triglycerides ≤ 400 mg/dL were eligible for this study. The first patient was enrolled on 02 August 2011 and the last patient was enrolled on 20 February 2012.

Participant flow — Overall Study
MilestonePlaceboEvolocumab 350 mgEvolocumab 420 mg
Started565656
Received treatment565556
Completed565556
Not completed010
Withdrew: Other010

Outcome measures

PrimaryPercent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

LDL-C was measured using ultracentrifugation.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
percent changePlaceboEvolocumab 350 mgEvolocumab 420 mg
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 121.12 ± 2.88-42.70 ± 2.93-55.24 ± 2.88
Statistical analysis
  • Placebo vs Evolocumab 350 mg · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -43.82 · 95% CI -51.56 to -36.09Placebo is the reference.
  • Placebo vs Evolocumab 420 mg · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -56.36 · 95% CI -64.06 to -48.67Placebo is the reference
SecondaryAbsolute Change From Baseline in LDL-C at Week 12

LDL-C was measured using ultracentrifugation.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in LDL-C at Week 12
mg/dLPlaceboEvolocumab 350 mgEvolocumab 420 mg
Absolute Change From Baseline in LDL-C at Week 124.2 ± 5.2-61.3 ± 5.4-80.5 ± 5.2
Statistical analysis
  • Placebo vs Evolocumab 350 mg · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -65.5 · 95% CI -79.6 to -51.4Placebo is the reference
  • Placebo vs Evolocumab 420 mg · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -84.7 · 95% CI -98.8 to -70.7Placebo is the reference
SecondaryPercent Change From Baseline in Non-High Density Lipoprotein Cholesterol (HDL-C) at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (HDL-C) at Week 12
percent changePlaceboEvolocumab 350 mgEvolocumab 420 mg
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (HDL-C) at Week 122.48 ± 2.80-39.31 ± 2.86-50.98 ± 2.80
Statistical analysis
  • Placebo vs Evolocumab 350 mg · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -41.79 · 95% CI -49.32 to -34.26Placebo is the reference
  • Placebo vs Evolocumab 420 mg · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -53.46 · 95% CI -60.95 to -45.97Placebo is the reference
SecondaryPercent Change From Baseline in Apolipoprotein B at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B at Week 12
percent changePlaceboEvolocumab 350 mgEvolocumab 420 mg
Percent Change From Baseline in Apolipoprotein B at Week 122.86 ± 2.61-31.89 ± 2.66-43.34 ± 2.61
Statistical analysis
  • Placebo vs Evolocumab 350 mg · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -34.75 · 95% CI -41.77 to -27.74Placebo is the reference
  • Placebo vs Evolocumab 420 mg · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -46.20 · 95% CI -53.18 to -39.23Placebo is the reference
SecondaryPercent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12
percent changePlaceboEvolocumab 350 mgEvolocumab 420 mg
Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 122.98 ± 2.73-33.69 ± 2.79-42.03 ± 2.73
Statistical analysis
  • Placebo vs Evolocumab 350 mg · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -36.66 · 95% CI -44.01 to -29.32Placbo is the reference
  • Placebo vs Evolocumab 420 mg · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -45.01 · 95% CI -52.32 to -37.70Placebo is the reference
SecondaryPercent Change From Baseline in Apolipoprotein B /Apolipoprotein A-1 Ratio at Week 12
Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B /Apolipoprotein A-1 Ratio at Week 12
percent changePlaceboEvolocumab 350 mgEvolocumab 420 mg
Percent Change From Baseline in Apolipoprotein B /Apolipoprotein A-1 Ratio at Week 12-4.10 ± 2.53-38.02 ± 2.58-48.74 ± 2.53
Statistical analysis
  • Placebo vs Evolocumab 350 mg · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -33.92 · 95% CI -40.72 to -27.11Placebo is the reference
  • Placebo vs Evolocumab 420 mg · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -44.64 · 95% CI -51.41 to -37.86Placebo is the reference

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/56 (0%)24/56 (42.9%)
Evolocumab 350 mg—0/55 (0%)22/55 (40%)
Evolocumab 420 mg—2/56 (3.6%)19/56 (33.9%)
Most frequent serious events
Most frequent serious events
EventPlaceboEvolocumab 350 mgEvolocumab 420 mg
Atrial fibrillationCardiac disorders0/560/551/56
AppendicitisInfections and infestations0/560/551/56
Postoperative wound infectionInfections and infestations0/560/551/56
Most frequent other events
Most frequent other events
EventPlaceboEvolocumab 350 mgEvolocumab 420 mg
NasopharyngitisInfections and infestations6/567/557/56
InfluenzaInfections and infestations6/561/554/56
Injection site painGeneral disorders1/565/552/56
HeadacheNervous system disorders5/563/553/56
SinusitisInfections and infestations1/563/551/56
Upper respiratory tract infectionInfections and infestations0/563/552/56
DiarrhoeaGastrointestinal disorders3/560/552/56
NauseaGastrointestinal disorders3/561/551/56
Pain in extremityMusculoskeletal and connective tissue disorders3/560/550/56
CoughRespiratory, thoracic and mediastinal disorders3/561/550/56

Baseline characteristics

Full analysis set (all randomized participants who received at least 1 dose of investigational product).

Age, Continuous
Age, Continuous(years)PlaceboEvolocumab 350 mgEvolocumab 420 mgTotal
Mean49.3 ± 11.347.6 ± 13.651.8 ± 13.049.6 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEvolocumab 350 mgEvolocumab 420 mgTotal
Female32252178
Male24303589
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboEvolocumab 350 mgEvolocumab 420 mgTotal
Hispanic or Latino2002
Not Hispanic or Latino545556165
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboEvolocumab 350 mgEvolocumab 420 mgTotal
Asian3137
Black or African American0314
White484852148
Other4307
Mixed Race1001
Stratification Factor: LDL-C Level
Stratification Factor: LDL-C Level(participants)PlaceboEvolocumab 350 mgEvolocumab 420 mgTotal
< 130 mg/dL19171955
≥ 130 mg/dL373837112
Stratification Factor: Baseline Use Of Ezetimibe
Stratification Factor: Baseline Use Of Ezetimibe(participants)PlaceboEvolocumab 350 mgEvolocumab 420 mgTotal
No20192059
Yes363636108
LDL-C Concentration
LDL-C Concentration(mg/dL)PlaceboEvolocumab 350 mgEvolocumab 420 mgTotal
Mean160.8 ± 44.0156.8 ± 46.1149.5 ± 36.3155.7 ± 42.3
Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration
Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration(mg/dL)PlaceboEvolocumab 350 mgEvolocumab 420 mgTotal
Mean182.7 ± 52.6178.0 ± 51.7171.0 ± 43.6177.2 ± 49.4

3 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012 Nov 13;126(20):2408-17. doi: 10.1161/CIRCULATIONAHA.112.144055. Epub 2012 Nov 5. PubMed 23129602 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2011 to primary completion in May 2012, 9 months.

Results were first posted in Sep 2015, 3 years 4 months after primary completion. A results delay was requested in Apr 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2011
First posted
Jun 17, 2011
StartActual
Aug 2, 2011
Primary completionActual
May 16, 2012
CompletionActual
May 16, 2012
Results delay requested
Apr 2, 2013
Results first posted
Sep 29, 2015
Last update
Nov 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01375751
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 17, 2011
Start date
Aug 2, 2011
Primary completion
May 16, 2012
Completion
May 16, 2012
Results posted
Sep 29, 2015
Last update
Nov 15, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion